MP07-09 12-MONTH ANALYSIS OF ILLUMINATE-A, A PHASE 3 STUDY OF LUMASIRAN: SUSTAINED OXALATE LOWERING AND KIDNEY STONE EVENT RATES IN PRIMARY HYPEROXALURIA TYPE 1Dean G. Assimos, John C. Lieske, David J. Sas et al.|The Journal of Urology|2021Cited by 0